(MedPage Today) — The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the market…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119806
Author :
Publish date : 2026-02-09 20:19:00
Copyright for syndicated content belongs to the linked Source.
